Effect of endoscopic ultrasound-guided radiofrequency ablation, on overall survival, in patients with locally advanced pancreatic adenocarcinoma: a multicenter randomized controlled clinical trial
dc.contributor
dc.contributor.author
dc.contributor.other
dc.date.accessioned
2017-06-20T22:14:56Z
dc.date.available
2017-06-20T22:14:56Z
dc.date.issued
2017-01
dc.identifier.uri
dc.description.abstract
Background: Pancreatic cancer is the fourth leading cause of cancer related death in the
Western world. At time of diagnosis, 20% of patients present with a resectable tumour, 40% with an
irresectable locally advanced tumor (without metastases) and 40% with metastatic disease. The
median survival of patients with irresectable locally advanced pancreatic cancer is only 6 months.
Currently, there is no effective treatment for these patients
Importance: There is an urgent need for new therapeutical options in pancreatic
adenocarcinoma. Radiofrequency ablation (RFA) is a technique that has been demonstrated to be
effective in the treatment of several irresectable tumours such as liver and lung neoplasms. RFA
produces local tumour destruction from an electrode implanted directly into the tumour causing
frictional heating.
Objective: To evaluate whether endoscopic ultrasound-guided radiofrequency ablation (EUSRFA)
plus conventional treatment (chemotherapy ± radiotherapy) improves overall survival in patients
with non-resectable locally advanced pancreatic adenocarcinoma in comparison to protocolised
treatment. The overall survival will be analysed 2 and 5 years after finishing the treatment. It will be
also determined the safety of the procedure. So, complications after the intervention will be
registered. Moreover, a pain score, length of hospital stay, type of chemotherapy received,
radiotherapy, and progression free survival will be determined.
Design: A multicenter open-labelled randomized interventional clinical trial will be carried out.
Patients with pancreatic cancer, confirmed anatomopathologically, will be introduced into the study
performed in universitary centers such as: Dr. Josep Trueta Hospital, Vall d’Hebron Hospital, Bellvitge
Hospital and Hospital Clinic of Barcelona.
Methods: A total of 274 patients are needed to complete the study. Group A (137 patients),
will be treated with chemotherapy ± radiotherapy (QT±RT). Group B (137) EUS-RFA will be performed
before starting the protocolised treatment (QT±RT). For this procedure, it will be necessary the Habib
TM catheter, a monopolar radiofrequency system, connected to a generator. Also, a linear
ecoendoscope will be used to guide the intervention and visualize the surrounding anatomy.
Participants: Patients with non-metastatic locally advanced pancreatic cancer confirmed by
citology or biopsy without previous treatment and performance status between 0-2
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.relation.ispartofseries
Medicina (TFG)
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 Spain
dc.rights.uri
dc.subject
dc.title
Effect of endoscopic ultrasound-guided radiofrequency ablation, on overall survival, in patients with locally advanced pancreatic adenocarcinoma: a multicenter randomized controlled clinical trial
dc.type
info:eu-repo/semantics/bachelorThesis
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.coverage.geolocation
east=2.819998700000042; north=41.997504; name=Hospital Universitari de Girona Doctor Josep Trueta
east=2.1418727000000217; north=41.4278967; name=Hospital Universitari Vall d'Hebrón
east=2.151100000000042; north=41.388619; name=Hospital Clínic
east=2.107242000000042; north=41.344677; name=Hospital de Bellvitge
Localització